Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.

Journal of neuro-oncology - 1 Sept 2021

Sears Thomas K, Horbinski Craig M, Woolard Kevin D

Abstract excerpt

INTRODUCTION: A large subset of diffusely infiltrative gliomas contains a gain-of-function mutation in isocitrate dehydrogenase 1 or 2 (IDH1/2mut) which produces 2-hydroxglutarate, an inhibitor of α-ketoglutarate-dependent DNA demethylases, thereby inducing widespread DNA and histone methylation. Because histone deacetylase (HDAC) enzymes are localized to methylated chromatin via methyl-binding domain proteins,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma
Share to Histone Deacetylase Inhibitors
Share to Histones

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 34424450
DOI: 10.1007/s11060-021-03829-0
PMCID: PMC8437887

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.PMID 34424450Read ↗

HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma.Semantic proximity Read ↗

HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant gliomaSemantic proximity Read ↗

EZH2 inhibition sensitizes IDH1R132H mutant gliomas to histone deacetylase inhibitorSemantic proximity Read ↗

Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles.Semantic proximity Read ↗

Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in <i>IDH1</i> -mutant gliomaSemantic proximity Read ↗

Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.Semantic proximity Read ↗

Novel IDH1-Targeted Glioma Therapies.Semantic proximity Read ↗

Reprogramming the Immune Suppressive Tumor Microenvironment in Glioma Enhances the Efficacy of Immune-Mediated Gene TherapySemantic proximity Read ↗

A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.Semantic proximity Read ↗

Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.Semantic proximity Read ↗

Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.Semantic proximity Read ↗

Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.